UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Grows Stake in Privia Health Group, Inc. $PRVA

Key Points

• UBS Asset Management significantly increased its stake in Privia Health Group by 180.4% during the first quarter, owning approximately 2.16% of the company, valued at $59.1 million.
• Privia Health reported quarterly earnings with a net margin of 0.78%, achieving revenue of $521.15 million, exceeding expectations despite missing EPS estimates.
• Wall Street analysts maintain a consensus Moderate Buy rating for Privia Health Group, with a price target of $28.58, highlighting strong growth potential despite recent rating adjustments.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 180.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,633,040 shares of the company's stock after acquiring an additional 1,693,870 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 2.16% of Privia Health Group worth $59,112,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Van Berkom & Associates Inc. purchased a new stake in shares of Privia Health Group during the first quarter valued at $45,207,000. Nuveen Asset Management LLC boosted its position in shares of Privia Health Group by 19.8% during the fourth quarter. Nuveen Asset Management LLC now owns 1,488,979 shares of the company's stock valued at $29,110,000 after buying an additional 246,393 shares during the last quarter. Northern Trust Corp boosted its position in shares of Privia Health Group by 2.2% during the first quarter. Northern Trust Corp now owns 1,423,865 shares of the company's stock valued at $31,966,000 after buying an additional 31,224 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Privia Health Group during the first quarter valued at $26,899,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Privia Health Group by 5.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,192,362 shares of the company's stock valued at $26,769,000 after buying an additional 58,489 shares during the last quarter. 94.48% of the stock is owned by hedge funds and other institutional investors.

Privia Health Group Stock Performance

PRVA stock opened at $22.79 on Monday. Privia Health Group, Inc. has a fifty-two week low of $16.47 and a fifty-two week high of $26.09. The business's 50-day moving average is $21.11 and its two-hundred day moving average is $22.51. The company has a market cap of $2.80 billion, a price-to-earnings ratio of 207.20, a P/E/G ratio of 3.30 and a beta of 0.82.

Privia Health Group (NASDAQ:PRVA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.03). Privia Health Group had a return on equity of 2.13% and a net margin of 0.78%.The company had revenue of $521.15 million during the quarter, compared to the consensus estimate of $466.97 million. During the same period last year, the business earned $0.19 EPS. The firm's quarterly revenue was up 23.4% compared to the same quarter last year. Privia Health Group has set its FY 2025 guidance at EPS. Equities analysts predict that Privia Health Group, Inc. will post 0.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on PRVA shares. Zacks Research raised Privia Health Group from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 19th. Stephens reaffirmed an "overweight" rating and set a $32.00 price objective on shares of Privia Health Group in a research report on Thursday, September 4th. Citigroup reaffirmed an "outperform" rating on shares of Privia Health Group in a research report on Friday, August 29th. Evercore ISI dropped their price objective on Privia Health Group from $30.00 to $28.00 and set an "outperform" rating on the stock in a research report on Wednesday, July 9th. Finally, JMP Securities increased their price objective on Privia Health Group from $29.00 to $30.00 and gave the company a "market outperform" rating in a research report on Friday, August 29th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, Privia Health Group has an average rating of "Moderate Buy" and a consensus price target of $28.58.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.

Want to see what other hedge funds are holding PRVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Privia Health Group, Inc. (NASDAQ:PRVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.